Table 3.
Relative HARM incidence of patients according to stroke subtypes.
| TOAST |
p-Value |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total (n = 264) | 1. LAA (n = 75) | 2. SVO (n = 88) | 3. CE (n = 31) | 4. SOD (n = 4) | 5. SUD (n = 66) | Among subtypes | LAA vs. other subtypes | SVO vs. other subtypes | |||
| SUDm (n = 15) | SUDn (n = 40) | SUDi (n = 11) | |||||||||
| (A) OVERALL TOAST ETIOLOGIC SUBGROUPS | |||||||||||
| HARM (+) | 67 | 30 | 6 | 9 | 2 | 3 | 13 | 4 | <0.0001 | 0.001 | <0.0001 |
| HARM (−) | 197 | 45 | 82 | 22 | 2 | 12 | 27 | 7 | |||
| (B) LAA VS. OTHER SUBGROUP | |||||||||||
|
TOAST |
|||||||||||
| LAA (n = 75) | Others (n = 189) | p-Value | |||||||||
| HARM (+) (n = 67) | 30 (40%) | 37 (19.57%) | 0.001 | ||||||||
| HARM (−) (n = 197) | 45 (60%) | 152 (82.42%) | |||||||||
| (C) LAA PLUS CE VS. OTHER GROUP | |||||||||||
|
TOAST |
|||||||||||
| CE + LAA (n = 106) | Others (n = 158) | p-Value | |||||||||
| HARM (+) (n = 67) | 39 (36.79%) | 28 (17.72%) | <0.001 | ||||||||
| HARM (−) (n = 197) | 67 (63.21%) | 130 (82.28%) | |||||||||
| (D) SVO VS. OTHER SUBGROUPS | |||||||||||
|
TOAST |
|||||||||||
| SVO (n = 88) | Others (n = 176) | p-Value | |||||||||
| HARM (+) (n = 67) | 6 (6.81%) | 61 (34.65%) | <0.001 | ||||||||
| HARM (−) (n = 197) | 82 (93.18%) | 115 (65.34%) | |||||||||
HARM, hyperintense acute reperfusion marker; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; LAA, large artery atherosclerosis; SVO, small vessel occlusion; CE, cardioembolism; SOD, strokes of other determined etiology; SUD, strokes of undetermined etiology; SUDm, two or more causes; SUDn, negative evaluation; SUDi, incomplete evaluation.
Among the 264 patients with acute ischemic stroke, 67 (25.38%) patients were HARM positive while, 197 (74.62%) patients were HARM negative (A). (B) The relatively higher incidence of HARM in the LAA group (40%) than in the other subgroups (19.57%) (p = 0.001). (C) The relative HARM incidence in LAA plus CE (36.79%) subgroup was significantly higher compared with that in the other subgroups (17.72%) (p < 0.001). (D) A significantly lower incidence of HARM in the SVO subgroup (6.81%) than in the other subgroups (34.65%) (p < 0.001).